Migraine Trial, Recruiting NCT06652724 Sponsor: University of Roma La Sapienza Condition: Migraine
Back to Migraine

Migraine Trial, Recruiting

NCT06652724
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are at least 18 years old
  • You have had at least 5 years of formal education
  • You have been diagnosed with fibromyalgia (FM) according to specific medical guidelines (Wolfe, 2016), if joining the fibromyalgia group
  • You have been diagnosed with chronic migraine (CM) according to specific medical guidelines (Olesen, 2018), if joining the chronic migraine group
  • You have official medical documentation confirming both fibromyalgia and chronic migraine diagnoses, if joining the combined FibroMig group

Who may not be able to join:

  • You have a serious psychiatric condition or significant problems with memory or thinking
  • You have difficulty understanding or speaking Italian
  • You have a history of other conditions involving long-term pain (for those in the fibromyalgia or chronic migraine groups)
  • You have a history of other neurological (brain or nerve) conditions besides migraine (for those in the chronic migraine or FibroMig groups)
  • You have a history of other conditions affecting joints, muscles, or connective tissue besides fibromyalgia (for those in the fibromyalgia or FibroMig groups)
  • If joining as a healthy volunteer: you must not have fibromyalgia or chronic migraine, must not have serious psychiatric conditions or thinking/memory problems, must not have significant levels of depression, and must not have a history of neurological or rheumatological (joint/muscle) conditions (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Federica Galli, Professor, University of Roma La Sapienza

Phone: 3355492778

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Roma La Sapienza
Registry
ClinicalTrials.gov
Start date
17 September 2024
Est. completion
30 September 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

severity of pain; severity of symptoms; mental pain; level of central sensitization; psychopathological symptoms related to anxiety and depression; alexithymia level; quality of life

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov